Abstract Number: 0674 • ACR Convergence 2023
Efficacy and Safety of Mepolizumab During Maintenance Therapy in Patients with Eosinophilic Granulomatosis with Polyangiitis
Background/Purpose: Eosinophilic granulomatosis with polyangiitis (EGPA) is a small-vessel vasculitis characterized by asthma, hyper-eosinophilia, and progressive multiorgan organ involvement. Mepolizumab (MPZ) is a humanized monoclonal…Abstract Number: 0725 • ACR Convergence 2023
Real-life Use of the PEXIVAS Reduced-dose Glucocorticoid Regimen in Granulomatosis with Polyangiitis and Microscopic Polyangiitis
Background/Purpose: Glucocorticoids (GCs) in combination with rituximab (RTX) or cyclophosphamide are the cornerstone of treatment for patients with severe granulomatosis with polyangiitis (GPA) and microscopic…Abstract Number: 1545 • ACR Convergence 2023
Validation of the 2022 American College of Rheumatology/European Alliance of Associations for Rheumatology Classification Criteria in Patients with ANCA-associated Vasculitis
Background/Purpose: The early diagnosis of ANCA-associated vasculitis (AAV) and treatment initiation may prevent progression to end organ damage, particularly renal disease. Based on the Vasculitis…Abstract Number: 2381 • ACR Convergence 2023
ANCA-associated Vasculitis and Renal Disease in a Multidisciplinary Outpatient Clinic in Northern Spain
Background/Purpose: The severity of clinical features and outcomes in previous series of patients reported with renal disease related to ANCA-associated vasculitis (AAV) vary greatly, probably…Abstract Number: 0675 • ACR Convergence 2023
Investigating the Impact of anti-IL5 Therapy in the Management of Relapsing and Refractory Eosinophilic Granulomatosis with Polyangiitis (EGPA); A Three Year Longitudinal Perspective and Beyond
Background/Purpose: In the randomized, placebo-controlled MIRRA trial for relapsing and refractory eosinophilic granulomatosis with polyangiitis (EGPA), adjuvant therapy with 300mg anti-IL5 mAB Mepolizumab [MEPO] for…Abstract Number: 0854 • ACR Convergence 2023
Long-term Efficacy of Remission-induction Regimens for Eosinophilic Granulomatosis with Polyangiitis
Background/Purpose: The Rituximab in Eosinophilic Granulomatosis With Polyangiitis (REOVAS) trial compared rituximab (RTX) infusions to conventional strategy for remission-induction in eosinophilic granulomatosis with polyangiitis (EGPA).…Abstract Number: 1550 • ACR Convergence 2023
Importance of Shared Decision-Making for Patients with ANCA-Associated Vasculitis
Background/Purpose: ANCA-associated vasculitis (AAV) is a rare autoimmune disease associated with significant morbidity. It can present at any age and treatment needs change over time.…Abstract Number: 2382 • ACR Convergence 2023
Relapse of Patients with ANCA-associated Vasculitis Who Are on Dialysis
Background/Purpose: It is known that disease activity of ANCA-associated vasculitis (AAV) is decreased after dialysis. However, most studies have been conducted on Caucasians, and factors…Abstract Number: 0677 • ACR Convergence 2023
Analysis of Clinical Outcomes in Eosinophilic Granulomatosis with Polyangiitis (EGPA) Treated with Mepolizumab over 2 Years for Remission Induction or Maintenance: A Single Center Experience in Japan
Background/Purpose: Contrary to Western countries, MPO-ANCA-associated vasculitis (MPO-AAV) is dominant in Japan or Asian countries. It is possible that therapeutic responses to EGPA with mepolizumab…Abstract Number: 0855 • ACR Convergence 2023
Real-world Experience with Avacopan in ANCA Vasculitis: A Multi-center Retrospective Cohort Analysis
Background/Purpose: Avacopan (AVP) is a recently approved adjunct therapy for remission induction of ANCA-associated vasculitis (AAV). Data on real-world use of AVP in AAV are…Abstract Number: 1551 • ACR Convergence 2023
Measurement of Sinonasal Disease Activity in Granulomatosis with Polyangiitis
Background/Purpose: In granulomatosis with polyangiitis (GPA), sinonasal inflammation can be severe and significantly impact quality of life. Little is known about the most effective local…Abstract Number: 2383 • ACR Convergence 2023
Clinical Characteristics, Treatment Patterns, and Clinical Outcomes in Patients with Dual Positive Anti-Neutrophil Cytoplasmic Antibody and Anti-Glomerular Basement Membrane Antibody: A Single Center Experience
Background/Purpose: Knowledge of disease characteristics and long-term outcomes of dual-positive patients (DPP) exhibiting anti-neutrophil cytoplasmic antibodies (ANCA) and anti-glomerular basement membrane (GBM) antibodies is limited…Abstract Number: 0679 • ACR Convergence 2023
Long-term Safety of Rituximab (Mabthera) in Granulomatosis with Polyangiitis (GPA) or Microscopic Polyangiitis (MPA): Rituximab Surveillance Study in VASculitis (RIVAS)
Background/Purpose: Rituximab is a first-line treatment for remission induction and the prevention of relapse in ANCA-associated vasculitis (AAV). There is a paucity of real-world data…Abstract Number: 0856 • ACR Convergence 2023
Dupilumab for Relapsing or Refractory Eosinophilic Granulomatosis with Polyangiitis: A European Retrospective Study
Background/Purpose: Eosinophilic granulomatosis with polyangiitis (EGPA) is an ANCA-associated vasculitides characterized by asthma, blood and tissue eosinophilia and systemic manifestations. Glucocorticoids (GCs)-dependent asthma and/or disabling…Abstract Number: 1584 • ACR Convergence 2023
Effect of Trimethoprim Sulfamethoxazole Prophylaxis on Infections During Treatment of Granulomatosis with Polyangiitis with Rituximab: A Population-Based Study
Background/Purpose: Infections during treatment of ANCA-associated vasculitis (AAV) lead to excess mortality. Trimethoprim sulfamethoxazole (TMP-SMX), recommended for pneumocystis jirovecii pneumonia (PJP) prophylaxis, has broad antimicrobial…
- 1
- 2
- 3
- …
- 13
- Next Page »